Streetbeat News

ABSI

Absci Corporation

https://www.absci.com

Industry

Biotechnology

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Open

2.66

Mkt cap

293M

Volume

1.7M

High

2.69

P/E Ratio

-2.77

52-wk high

6.72

Low

2.52

Div yield

N/A

52-wk low

1.35

12 health care stocks showed significant movements in Thursday's pre-market session. CNS Pharma (CNSP) saw the highest gain, rising 109.5%, while Gain Therapeutics (GANX) experienced the largest decline, falling 15.5%.

Portfolio Pulse from Benzinga Insights

July 05, 2024 | 2:59 pm

Absci shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 11:40 am

Morgan Stanley has initiated coverage on Absci (NASDAQ:ABSI) with an Overweight rating and a price target of $7, as announced by analyst Vikram Purohit.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 9:24 am

Cathie Wood's Ark Invest sold 3,341 shares of Coinbase amidst a volatile cryptocurrency market, with Bitcoin dropping below $62,000. Other significant trades included selling shares of Teladoc Health and Verve Therapeutics, and buying shares of Absci Corp and Roku.

Portfolio Pulse from Benzinga Neuro

June 25, 2024 | 3:17 am

Several major stocks, including AMC Networks, Louisiana-Pacific, and others, are experiencing declines in Monday's pre-market session. AMC Networks fell sharply due to a private offering of convertible senior notes, while Louisiana-Pacific was downgraded by Goldman Sachs.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 11:41 am

Ark Invest, led by Cathie Wood, made significant trades involving Robinhood Markets, Moderna, Palantir Technologies, and Advanced Micro Devices. Ark reduced its holdings in Robinhood and Moderna while increasing its positions in Palantir and AMD.

Portfolio Pulse from Benzinga Neuro

May 30, 2024 | 2:57 am

Six analysts have recently shared their insights on Absci (NASDAQ:ABSI), with a mix of bullish and somewhat bullish ratings. The average 12-month price target for Absci is $8.83, reflecting a 26.14% increase from the previous target. Analysts have maintained or raised their ratings, with price targets ranging from $7.00 to $13.00. Despite revenue challenges and below-average ROE and ROA, Absci's net margin and debt management are strong.

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 1:00 pm

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Absci (NASDAQ:ABSI) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 10:47 am

Absci (NASDAQ:ABSI) reported Q1 2024 earnings with a GAAP EPS of $(0.22), missing the $(0.21) estimate, and sales of $898K, missing the $2.419M estimate. This represents a 15.38% decrease in losses per share and a 29.24% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:31 am

BlackBerry Limited announced a collaboration with Advanced Micro Devices, Inc. to enhance next-generation robotic systems, causing its shares to rise 9%. Other stocks like Nurix Therapeutics, Taysha Gene Therapies, and Tesla also saw significant gains due to various factors including strategic collaborations, analyst ratings, and annual reports.

Portfolio Pulse from Avi Kapoor

April 09, 2024 | 2:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.